Combination Therapy for Alcohol Abstinence

Evidence for Medication Selection

• The combination of acamprosate and naltrexone showed improved abstinence versus placebo (OR 3.68, 95% CI 1.50-9.02), according to a 2020 network meta-analysis 1
• The evidence for the combination of acamprosate and naltrexone was rated as moderate quality due to low numbers of studies and patients 2, 3
• Acamprosate alone had moderate-quality evidence for maintaining abstinence, while naltrexone's evidence was weaker 2

Clinical Guidelines

• The British Medical Journal recommends using acamprosate 1998 mg/day (if ≥60 kg) as first-line for maintaining abstinence in detoxified patients, particularly in primary care settings 2, 3
• The National Institute for Health and Care Excellence guidelines suggest using acamprosate exclusively for patients with liver disease, as naltrexone is contraindicated in hepatic insufficiency 4

Critical Considerations

• The American College of Physicians advises against using naltrexone in patients with alcoholic liver disease due to hepatotoxicity risk and formal contraindication 4, 5